Biotech | March 12, 2024
USFDA grants Orphan Drug Designation for iOnctura's first-in-class autotaxin cancer therapy
It is the first autotaxin inhibitor to be investigated in cancer patients
It is the first autotaxin inhibitor to be investigated in cancer patients
Shivalik Rasayan Limited have successfully submitted USMDF for API " Palbociclib " to USFDA
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
The company moves a step closer towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
The marketing authorisations for three generic drugs signifying advances in cancer treatment will considerably benefit thousands of patients by improving access, ensuring affordability
The unit will have installed manufacturing capacity of over 15 million vials annually that includes lyophilized vials, all in the anti-cancer segment
Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes
Subscribe To Our Newsletter & Stay Updated
